Considering its high versatility as a drug carrier, we suggest that Lmat-LLO could be engineered to express melanoma-associated antigens [21], so that the immune system of the body is boosted even further, or conjugated with a BRAF or a MEK inhibitor, providing an alternative way to assess the combined effects of immunotherapy and targeted therapy [22]. This evidence concerns the gene MAP2K7 and melanoma.